Advertisement

Hematology and Oncology

Home Hematology and Oncology
Immediate post-resection intravesical installation of gemcitabine is associated with reduced recurrence over four years for patients with suspected low-grade non-muscle-invasive urothelial cancer

Intravesical Gemcitabine Therapy Cuts Bladder Cancer Recurrence

Immediate post-resection gemcitabine reduces recurrence over 4 years in low-grade bladder cancer
The cancer burden among persons living with HIV is projected to shift by 2030

Cancer Incidences and Burden Expected to Shift in HIV-Positive

Prostate and lung cancer expected to emerge as the most common types by 2030
Two anti-cancer drugs administered together have been approved by the U.S. Food and Drug Administration to treat BRAF-positive anaplastic thyroid cancer.

FDA Approves Drug Combo for Aggressive Thyroid Cancer

Dabrafenib + trametinib approved to treat BRAF-positive anaplastic thyroid cancer
The likelihood of having breast cancer with a poor prognosis is increased for cancer diagnosed after a screening mammography with negative results

Poor Prognosis for Interval Breast Cancer After Negative Mammo

Odds of poor prognosis after mammography with negative results higher for younger women
Among women with metastatic cancer and dependent children

Parenting Fears Harm Well-Being of Women With Metastatic Cancer

Findings based on survey of women with advanced cancer and dependent children
Breast cancer screening is associated with less aggressive treatment

Screening Mammos Linked to Less Aggressive Tx If Diagnosed

Women aged 40 to 49 years with no mammogram have increased odds of positive nodes, larger tumors
For breast cancer patients undergoing treatments that are high risk for the development of breast cancer-related lymphedema (BCRL)

Early Intervention May Reduce Breast CA-Related Lymphedema

Bioimpedance spectroscopy monitoring with early interventions lowers need for aggressive treatment
Many organizations are not meeting the trial registration and results reporting requirements clarified by "The Final Rule

Many Organizations Not Meeting Trial Reporting Requirements

Only 19 percent of organizations use computer software to monitor compliance with Final Rule
Specific demographic groups have lower cancer genetic testing

Gender Disparity Observed in Cancer Genetic Testing in the U.S.

Unaffected men have rate of breast/ovarian cancer testing that is one-tenth that of unaffected women
The introduction of public reporting of surgeon specific 90-day postoperative mortality in elective colorectal cancer surgery is associated with a reduction in observed 90-day mortality

Reporting Outcomes Per Surgeon Tied to Drop in CRC Sx Mortality

Reduction in mortality with intro of public reporting of surgeon specific 90-day post-op mortality